Opdivo misses survival endpoint in Phase III for SCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said Opdivo nivolumab missed the primary endpoint of improving overall survival (OS) in the Phase III CheckMate -331 trial to treat small cell lung cancer in patients who relapsed following platinum-based chemotherapy. The anti-PD-1 mAb has accelerated approval in the U.S. to treat metastatic SCLC with progression after platinum-based chemotherapy and at least one other line of therapy (see "Opdivo Gets Accelerated Approval

Read the full 678 word article

User Sign In